Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment
A delta TGR exceeding 100 best identified HPD patients in the advanced melanoma population treated with anti-PD-1 monotherapy. Hyperprogression was notably prevalent in mucosal melanoma patients with multiple metastatic organs. Caution against HPD is warranted when applying anti-PD-1 monotherapy in mucosal subtype.
Authors
- Lu Si (ORCID: https://orcid.org/0000-0002-2123-9761)
- Xinan Sheng (ORCID: https://orcid.org/0000-0001-9359-0975)
- Bixia Tang (ORCID: https://orcid.org/0000-0002-3458-461X)
- Xue Bai (ORCID: https://orcid.org/0000-0002-5203-4080)
- Min Cao (ORCID: https://orcid.org/0000-0003-2324-3198)
- Bin Lian (ORCID: https://orcid.org/0000-0003-0090-1290)
- Zhihong Chi (ORCID: https://orcid.org/0009-0005-1504-7842)
- Lili Mao (ORCID: https://orcid.org/0000-0003-3236-352X)
- Li Zhou (ORCID: https://orcid.org/0000-0002-9331-0600)
- Siming Li (ORCID: https://orcid.org/0000-0001-7077-0404)
- Ying-Shi Sun
- Xuan Wang (ORCID: https://orcid.org/0000-0002-4871-6441)
- Haibin Zhu
- Xieqiao Yan (ORCID: https://orcid.org/0000-0002-1781-3193)
- Jun Guo (ORCID: https://orcid.org/0000-0001-8573-5556)
- Chuanliang Cui (ORCID: https://orcid.org/0000-0001-6455-0843)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1093/oncolo/oyae211
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals
- National Key Research and Development Program of China